Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress

Jasper Therapeutics, Inc.

Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.
BEACON CSU investigation rules out drug substance/product issues; focus shifts to clinical site activity.
Investigation completion expected in Q4 2025 with KOL panel review for Phase 2b CSU study integration.
Use of proceeds: continued development of briquilimab in mast-cell diseases and general corporate expenses.
Common warrants exercisable at $2.92, 6-month lockout, 4-year term; pre-funded warrants at $0.0001 exercise.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.